Table 1.
Data collected for the retrospective analysis of chemotherapy costs.
Table 2.
Summary of patient characteristics in the chemotherapy costing analysis.
Table 3.
Cost of adjuvant chemotherapy by components for societal and payer perspective.
Table 4.
Summary cost-effectiveness results for Oncotype DX versus standard care to inform adjuvant chemotherapy decision making in French private hospitals.
Fig 1.
Cost-effectiveness scatterplot of the probabilistic sensitivity analysis.
The cost-effectiveness scatterplot shows incremental costs (€) versus incremental effectiveness expressed in quality-adjusted life years (QALYs) for the comparison of Oncotype DX with standard care. Each blue point represents one iteration of the probabilistic sensitivity analysis (with data based on sampling from distributions around clinical and cost parameters). The red point indicates the mean (of 1,000 iterations).
Table 5.
Summary of one-way sensitivity analysis outcomes for Oncotype DX testing versus standard care.